New strategies in kidney cancer: Therapeutic advances through understanding the molecular basis of response and resistance

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1348-1354

  Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMG 386; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CONTRAST MEDIUM; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EVEROLIMUS; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PERIFOSINE; PROTEIN KINASE B INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; VON HIPPEL LINDAU PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; GENE EXPRESSION; GENOTYPE; HAPLOTYPE; HUMAN; HYPERTENSION; IMMUNOCOMPETENT CELL; KIDNEY CARCINOMA; KIDNEY FAILURE; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; TRANSLATIONAL RESEARCH;

EID: 77649134498     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2273     Document Type: Article

References (54)

1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
2. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370: 2103-11.
3. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.N Engl JMed 2007;356:2271-81.
4. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356: 115-24.
6. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26:5422-8.
7. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26: 3743-8.
8. Choueiri TK, Vaziri SA, Jaeger E, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008;180:860-5, discussion 5-6.
9. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.
10. DePrimo SE, Bello CL, Smeraglia J, et al. Soluble protein biomarkers of pharmacodynamic activity of the multitargeted kinase inhibitor SU11248 in patients with metastatic renal cell carcinoma. Proc Am Assoc Cancer Res 2005;46:464.
11. Escudier BJ, Taylor M, Koscielny S, et al. Circulating endothelial cells and progenitor cells in metastatic renal cell carcinoma: Predictive value during antiangiogenic therapy [abstract]? Genitourinary Cancers Symposium. 2008, p. 390.
12. Vroling L, Van der Veldt AAM, De Haas RR, Schuurhuis GJ, Van Cruijsen H. CD34bright/CD133neg candidate circulating endothelial progenitor cells (ccEPCs) are a potential biomarker during treatment with sunitinib or bevacizumab. Proceedings of the 99th AACR Annual Meeting, San Diego (CA). 2008, Abstract 4956.
13. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: Importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 2010;194:157-65.
14. Schor-Bardach R, Alsop DC, Pedrosa I, et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 2009;251:731-42.
15. de Bazelaire C, Alsop DC, George D, et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 2008;14:5548-54.
16. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008;26: 4572-8.
17. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;13:1801-9.
18. Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006;42:2472-9.
19. Rini BI, Schiller JH, Fruehauf JP, et al. Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736). J Clin Oncol 2008;26:3543.
20. Rini BI, Cohen DP, Lu DR, et al. Hypertension is a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. Proceedings of the 8th International Kidney Cancer Symposium, Chicago (IL). 2009 Sept. 25-26th.
21. Harzstark AL, Halabi S, Stadler WM, et al. Hypertension is associated with clinical outcome for patients (pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206. Proceedings of the Genitourinary Cancer Symposium. San Francisco. 2010 March 5-7th.
22. Rixe O, Dutcher J, Motzer R, et al. Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). J Clin Oncol 2009;27:5045.
23. van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009;27:4406-12.
24. Kim JJ, Vaziri SA, Elson P, et al. VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts). J Clin Oncol 2009;27:5005.
25. Bartsch G, Jr., Eggert K, Soker S, Bokemeyer C, Hautmann R, Schuch G. Combined antiangiogenic therapy is superior to single inhibitors in a model of renal cell carcinoma. J Urol 2008;179:326-32.
26. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1432-9.
27. Rini BI, Garcia JA, Cooney MM, et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009;15: 6277-83.
28. Sosman JA, Flaherty KT, Atkins MB, et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008;26:5011.
29. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
30. Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005;11:992-7.
31. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75.
32. Fernando NT, Koch M, Rothrock C, et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 2008;14:1529-39.
33. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999;5:2726-34.
34. Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and anti-tumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27:3557-65.
35. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6: 507-16.
36. Hong D, Gordon M, Appleman L, et al. Interim results from a phase 1b study of safety, pharmacokinetics and tumor response of the angiopoietin1/2- neutralizing peptibody AMG 386 in combination with AMG 706 (motesanib), bevacizumab or sorafenib in advanced solid tumors. Proceedings of the ESMO Congress, Stockholm, Sweden. 2008.
37. Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-75.
38. Panka D, Kumar M, Schor-Bardach R, et al. Mechanism of acquired resistance to sorafenib in RCC. AACR Meeting Abstracts. 2008, p. 2500.
39. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
40. Rini BI, Hutson TE, Elson P, et al. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma. Proceedings of the Genito-urinary Cancer Symposium. San Francisco. 2010 March 5-7th.
41. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22: 159-68.
42. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.
43. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4:1533-40.
44. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101.
45. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 2008;283:34495-9.
46. Vogelzang NJ, Hutson TE, Samlowski W, et al. Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor. J Clin Oncol 2009; 27:5034.
47. Merchan JR, Pitot HC, Qin R, et al. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC):Safety and activity in RTKI refractory RCC patients. J Clin Oncol 2009;27:5039.
48. Whorf RC, Hainsworth JD, Spigel DR, et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 2008;26:5010.
49. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
50. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82.
51. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009;69: 2506-13.
52. Gordon MS, Stein M, Shannon P, et al. Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009;27:5115.
53. Motzer RJ, Hudes G, Wilding G, et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009;7:28-33.
54. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32.